Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article provides a narrative on managing dermatologic side effects from cancer therapies and suggests strategies that oncologists could adopt, but it reports no new clinical findings.

In this study, the researchers identified that perturbing both AKT1 and MDM2 significantly reduces epithelial-mesenchymal transition in melanoma, proposing Cialis and Finasteride as potential therapeutic candidates with favorable properties for managing aggressive melanoma.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.